The resistance of bacteria to antimicrobials is a natural phenomenon that is inevitable in the health care setting. To slow the rate of antimicrobial reesistance, measures should be taken to improve infection control, develop new antimicrobials, and ensure the judicious use of currently available antimicrobials.1 Linezolid, the first available oxazolidinone, is used to treat infections with methicillin- resistant Staphylococcus aureus, vancomycin-resistant enterococci (VRE), and S. aureus with intermediate susceptibility to glycopeptides. The rate of linezolid resistance has not exceeded 0.5% in most health care institutions.2 The micro-organisms that most commonly develop resistance to linezolid are enterococci, primarily VRE. The appearance of linezolid-resistant VRE (LRVRE) is cause for concern, as only two other treatment options—daptomycin and quinupristin–dalfopristin—are available. Enterococci have become multidrug-resistant organisms owing mainly to poor infection-control practices and antimicrobial overuse.3 These gram-positive facultative bacteria belong to two species, Enterococcus faecalis and Enterococcus faecium, with the latter being the most pathogenic. Although these bacteria are considered normal flora in the intestinal tract, enterococci have been linked to infections that occur in health care settings, such as nosocomial bacteremia and urinary-tract and surgical-wound infections. Enterococci are unlikely pathogens for respiratory infections such as pneumonia.